Asendin: Effective Relief for Major Depressive Disorder
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.17 (0%) | 🛒 Add to cart |
| 60 | $1.20 | $82.33 $72.29 (12%) | 🛒 Add to cart |
| 90 | $1.14 | $123.50 $102.42 (17%) | 🛒 Add to cart |
| 120 | $1.10 | $164.67 $132.54 (20%) | 🛒 Add to cart |
| 180 | $1.07 | $247.00 $192.78 (22%) | 🛒 Add to cart |
| 270 | $1.05 | $370.50 $283.15 (24%) | 🛒 Add to cart |
| 360 | $1.03
Best per pill | $494.00 $370.50 (25%) | 🛒 Add to cart |
Asendin (amoxapine) is a tetracyclic antidepressant medication approved for the treatment of major depressive disorder. It functions primarily by inhibiting the reuptake of norepinephrine, thereby increasing its availability in the synaptic cleft and enhancing neurotransmission. Clinical evidence supports its efficacy in managing symptoms of depression, particularly in cases where other antidepressants have proven insufficient. Proper diagnosis and ongoing monitoring by a healthcare professional are essential for safe and effective use.
Features
- Active ingredient: amoxapine
- Available in 25 mg, 50 mg, 100 mg, and 150 mg oral tablets
- Tetracyclic antidepressant pharmacologic class
- Prescription-only medication
- Manufactured under strict quality control standards
Benefits
- Provides relief from symptoms of major depressive disorder, including low mood, anhedonia, and fatigue
- May offer faster onset of therapeutic effect compared to some SSRIs in certain patient profiles
- Helps restore functional capacity and improve overall quality of life
- Supports neurotransmitter balance through targeted norepinephrine reuptake inhibition
- May be suitable for patients who have not responded adequately to first-line antidepressant therapies
Common use
Asendin is indicated for the treatment of major depressive disorder (MDD) in adults. It is typically prescribed when a patient’s symptoms are moderate to severe and have persisted for a significant duration. Healthcare providers may consider Asendin particularly in cases where there is a history of partial or non-response to other antidepressant medications. It is not approved for use in pediatric populations.
Dosage and direction
The initial dosage for most adults is 50 mg to 75 mg daily, administered orally in divided doses. Depending on individual tolerance and therapeutic response, the dosage may be gradually increased. The maximum recommended daily dose is 300 mg for outpatients and 600 mg for inpatients under close supervision. Dosage adjustments should be made under the guidance of a healthcare provider, and full therapeutic effect may take several weeks to manifest.
Precautions
Patients should be monitored for worsening depression, suicidality, or unusual changes in behavior, especially during the initial months of therapy or following dosage changes. Asendin may cause drowsiness or dizziness; patients should avoid driving or operating machinery until they know how the medication affects them. Caution is advised in patients with a history of seizures, cardiovascular disease, hepatic impairment, or urinary retention. Regular follow-up and laboratory monitoring may be required.
Contraindications
Asendin is contraindicated in patients with known hypersensitivity to amoxapine or any component of the formulation. It should not be used concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to the risk of serotonin syndrome. Additional contraindications include acute recovery phase after myocardial infarction and severe hepatic impairment.
Possible side effect
Common side effects may include drowsiness, dry mouth, constipation, blurred vision, and dizziness. Less frequently, patients may experience orthostatic hypotension, weight gain, increased sweating, or urinary retention. Serious side effects such as seizures, tachycardia, extrapyramidal symptoms, neuroleptic malignant syndrome, and agranulocytosis have been reported rarely. Patients should report any persistent or severe adverse reactions to their healthcare provider.
Drug interaction
Asendin may interact with MAOIs, leading to potentially fatal serotonin syndrome. Concomitant use with other CNS depressants (e.g., alcohol, benzodiazepines, opioids) may enhance sedative effects. It may also interact with antihypertensive agents, anticonvulsants, and drugs that prolong the QT interval. Healthcare providers should review all concomitant medications, including over-the-counter products and herbal supplements, before initiating therapy.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to make up for a missed one is not recommended.
Overdose
Overdose of Asendin can be life-threatening and may manifest as severe drowsiness, tachycardia, hypotension, seizures, coma, or cardiac arrhythmias. Immediate medical attention is required. Treatment is supportive and may include gastric lavage, activated charcoal, and management of symptoms such as seizures or arrhythmias in a critical care setting.
Storage
Store at room temperature (20°–25°C or 68°–77°F), in a tightly closed container, away from light, moisture, and heat. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient needs and responses may vary.
Reviews
Clinical studies and patient reports indicate that Asendin can be effective in reducing symptoms of depression in appropriate patient populations. Some users note improvement in energy and mood within several weeks of initiation. However, experiences with side effects vary, and adherence to prescribed dosing and monitoring recommendations is critical for optimal outcomes.